



7th December 2011

Company's Announcement Office
ASX Limited
Exchange Centre
20 Bridge Street
Sydney NSW 2000

ASX ANNOUNCEMENT / MEDIA RELEASE

Japanese Patent for "Use of Metal Complexes" Granted

- **Patent covers the use of Mix&Go™ to facilitate binding processes**
- **Further strengthens Anteo's IP protection & commercial position**
- **Increased dialogue with potential customers**

Anteo Diagnostics Limited (ASX: ADO) today announced that the Japanese Patent Office has granted the "Use of Metal Complexes" patent for Mix&Go™.

It is unusual that patents are granted in Japan as quickly as this. Its granting provides Anteo with further confidence in the quality of the science and security over the intellectual property (IP) in a commercially large jurisdiction.

There are many commercially important reasons to bind biological molecules onto synthetic materials. These molecules are often fragile and do not react well when exposed to non-biological conditions. Mix&Go™ has been demonstrated to allow them to retain their activity when bound.

The "Use of Metal Complexes" patent covers the IP for the use of Mix&Go™ to facilitate this important binding process.

Anteo has demonstrated that the benefits of Mix&Go™ over existing methods are both numerous and significant from technical and commercial perspectives. Further, the Mix&Go™ technology has broad applications in non-biological markets.

This is another important patent to be granted to Anteo in a key market and marks another critical step in the continued effort to strengthen the IP of the Mix&Go™ technology.

Anteo's Chief Executive Officer Dr. Geoff Cumming commented "Anteo is extremely pleased to be granted the "Use of Metal Complexes" patent. In particular we were pleased with the outcome given the relative difficulty of achieving such grants in Japan.

Anteo Diagnostics Limited ABN 78 090 487 273

Unit 4, 26 Brandl Street, Eight Mile Plains Qld 4113

Phone 07 3219 0085 Fax 07 3219 0553 Email contact@anteodx.com Web www.anteodx.com



anteo diagnostics
limited

“As we continue to advance negotiations for new licensing agreements, protecting the Mix&Go™ technology is of critical importance for Anteo.”

Anteo is also pleased to inform shareholders that the company has progressed dialogue with potential customers in recent months. As previously explained, these negotiations take a significant amount of time due to the due diligence considered necessary by interested parties before incorporating Mix&Go™ into their commercial products.

ENDS

**For More Information Contact
Dr Geoff Cumming, CEO
Anteo Diagnostics Limited
Tel: +61 2 8823 3110**

***Anteo Diagnostics Limited* ABN 78 090 487 273
Unit 4, 26 Brandl Street, Eight Mile Plains Qld 4113**

Phone 07 3219 0085 Fax 07 3219 0553 Email contact@anteodx.com Web www.anteodx.com

For personal use only